Robert Coleman, Frcp

List of Publications by Year
in descending order

48 papers	2,656 citations	257450 24 h-index	189892 50 g-index

52 all docs	52 docs citations	52 times ranked	3693 citing authors

#	Article	IF	Citations
1	Correlation between targeted RNAseq signature of breast cancer CTCs and onset of bone-only metastases. British Journal of Cancer, 2022, 126, 419-429.	6.4	10
2	Experience with denosumab (XGEVAÂ®) for prevention of skeletal-related events in the 10 years after approval. Journal of Bone Oncology, 2022, 33, 100416.	2.4	21
3	Code of practice needed for samples donated by trial participants. Lancet Oncology, The, 2022, 23, e89-e90.	10.7	4
4	Off-treatment bone mineral density changes in postmenopausal women receiving anastrozole for 5 years: 7-year results from the IBIS-II prevention trial. British Journal of Cancer, 2021, 124, 1373-1378.	6.4	3
5	Natural history of stage II/III breast cancer, bone metastasis and the impact of adjuvant zoledronate on distribution of recurrences. Journal of Bone Oncology, 2021, 28, 100367.	2.4	4
6	Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial. Lancet Oncology, The, 2020, 21, 60-72.	10.7	161
7	Bisphosphonates and breast cancer â€“ From cautious palliation to saving lives. Bone, 2020, 140, 115570.	2.9	14
8	Adjuvant denosumab in early breast cancer â€“ Authors' reply. Lancet Oncology, The, 2020, 21, e125.	10.7	2
9	Individualized Bone-Protective Management in Long-Term Cancer Survivors With Bone Metastases. Journal of Bone and Mineral Research, 2020, 36, 1906-1913.	2.8	3
10	Clinical benefits of bone targeted agents in early breast cancer. Breast, 2019, 48, S92-S96.	2.2	12
11	Metastatic bone disease: Pathogenesis and therapeutic options. Journal of Bone Oncology, 2019, 15, 100205.	2.4	153
12	Associations Between Serum Bone Biomarkers in Early Breast Cancer and Development of Bone Metastasis: Results From the AZURE (BIG01/04) Trial. Journal of the National Cancer Institute, 2018, 110, 871-879.	6.3	32
13	Endocrine therapy and related issues in hormone receptor-positive early breast cancer: a roundtable discussion by the breast cancer therapy expert group (BCTEG). Breast Cancer Research and Treatment, 2018, 169, 1-7.	2.5	12
14	Cancer Treatment and Bone Health. Calcified Tissue International, 2018, 102, 251-264.	3.1	60
15	Bone health during endocrine therapy for cancer. Lancet Diabetes and Endocrinology,the, 2018, 6, 901-910.	11.4	85
16	Adjuvant zoledronic acid reduces fractures in breast cancer patients; an AZURE (BIG 01/04) study. European Journal of Cancer, 2018, 94, 70-78.	2.8	31
17	Pertuzumab for the Neoadjuvant Treatment of Early-Stage HER2-Positive Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Pharmacoeconomics, 2018, 36, 29-38.	3.3	12
18	Addition of gemcitabine to paclitaxel, epirubicin, and cyclophosphamide adjuvant chemotherapy for women with early-stage breast cancer (tAnGo): final 10-year follow-up of an open-label, randomised, phase 3 trial. Lancet Oncology, The, 2017, 18, 755-769.	10.7	18

#	Article	IF	Citations
19	Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trial. Lancet Oncology, The, 2017, 18, 929-945.	10.7	58
20	The role of biomarkers in the management of bone-homing malignancies. Journal of Bone Oncology, 2017, 9, 1-9.	2.4	71
21	Effect of MAF amplification on treatment outcomes with adjuvant zoledronic acid in early breast cancer: a secondary analysis of the international, open-label, randomised, controlled, phase 3 AZURE (BIG 01/04) trial. Lancet Oncology, The, 2017, 18, 1543-1552.	10.7	45
22	The value of biomarkers in bone metastasis. European Journal of Cancer Care, 2017, 26, e12725.	1.5	39
23	Long-Term Follow-Up of the Intergroup Exemestane Study. Journal of Clinical Oncology, 2017, 35, 2507-2514.	1.6	22
24	Bone targeted treatments in cancer â€“ The story so far. Journal of Bone Oncology, 2016, 5, 90-92.	2.4	12
25	Adjuvant Bone-Targeted Therapies for Postmenopausal Breast Cancer. JAMA Oncology, 2016, 2, 423.	7.1	6
26	Treatment of Metastatic Bone Disease and the Emerging Role of Radium-223. Seminars in Nuclear Medicine, 2016, 46, 99-104.	4.6	47
27	The impact of treatment compliance on fracture risk in women with breast cancer treated with aromatase inhibitors in the United Kingdom. Breast Cancer Research and Treatment, 2016, 155, 151-157.	2.5	32
28	Denosumab and fracture risk in women with breast cancer. Lancet, The, 2015, 386, 409-410.	13.7	21
29	Metastatic Prostate Cancer and the Bone: Significance and Therapeutic Options. European Urology, 2015, 68, 850-858.	1.9	74
30	Enhanced MAF Oncogene Expression and Breast Cancer Bone Metastasis. Journal of the National Cancer Institute, 2015, 107, djv256.	6.3	90
31	Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial. Lancet Oncology, The, 2014, 15, 738-746.	10.7	433
32	Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG) Tj ETQq0 0 0 rgBT /Overlock 10 T	10.7	247
33	A phase IIa, nonrandomized study of radium-223 dichloride in advanced breast cancer patients with bone-dominant disease. Breast Cancer Research and Treatment, 2014, 145, 411-418.	2.5	95
34	Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: a randomised, open label, non-inferiority phase 3 trial. Lancet Oncology, The, 2014, 15, 114-122.	10.7	109
35	Effects of Bone-Targeted Agents on Cancer Progression and Mortality. Journal of the National Cancer Institute, 2012, 104, 1059-1067.	6.3	171
36	Bone Oncologyâ€"An emerging multi-disciplinary specialty. Journal of Bone Oncology, 2012, 1, 1.	2.4	0

#	Article	IF	Citations
37	Zoledronic acid. Expert Opinion on Drug Safety, 2011, 10, 133-145.	2.4	36
38	The use of bisphosphonates in cancer treatment. Annals of the New York Academy of Sciences, 2011, 1218, 3-14.	3.8	66
39	Consensus on the utility of bone markers in the malignant bone disease setting. Critical Reviews in Oncology/Hematology, 2011, 80, 411-432.	4.4	84
40	Zoledronic acid use in cancer patients. Cancer, 2011, 117, 11-23.	4.1	46
41	New results from the use of bisphosphonates in cancer patients. Current Opinion in Supportive and Palliative Care, 2009, 3, 213-218.	1.3	22
42	Bone markers and their prognostic value in metastatic bone disease: Clinical evidence and future directions. Cancer Treatment Reviews, 2008, 34, 629-639.	7.7	108
43	Commentary: Controversies in NICE guidance on metastatic spinal cord compression. BMJ: British Medical Journal, 2008, 337, a2555-a2555.	2.3	4
44	Potential Use of Bisphosphonates in the Prevention of Metastases in Early-Stage Breast Cancer. Clinical Breast Cancer, 2007, 7, S29-S35.	2.4	23
45	Increased Levels of Urinary N-Telopeptide of Type I Collagen Correlate with Reduced Survival in Patients with Advanced Multiple Myeloma.. Blood, 2007, 110, 1499-1499.	1.4	1
46	Predictors for Skeletal-Related Events in Patients with Advanced Multiple Myeloma.. Blood, 2007, 110, 1482-1482.	1.4	1
47	Managing metastatic bone disease: Three case studies. Seminars in Oncology, 2004, 31, 83-86.	2.2	17
48	New Roles for Bisphosphonates in Cancer Therapy. Progress in Palliative Care, 1996, 4, 39-43.	1.2	7